Phorbol

Phorbol

SCHEMBL1893791

CC1=C[C@H]2[C@@]3(O)[C@H](C)[C@@H](O)[C@]4(O)[C@H]([C@@H]3C=C(CO)C[C@]2(O)C1=O)C4(C)C.CCCCCCCCCCCC(=O)OC(C)=O

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 5/20 0.69
PRKCG P05129 5/20 0.69
PRKD3 O94806 4/20 0.69
PRKCB P05771 4/20 0.69
PRKCH P24723 4/20 0.69
PRKCI P41743 4/20 0.69
PRKCE Q02156 4/20 0.69
PRKCQ Q04759 4/20 0.69
PRKCZ Q05513 4/20 0.69
PRKCD Q05655 4/20 0.69
PRKD1 Q15139 4/20 0.69
USP2 O75604 2/20 0.69
TP53 P04637 2/20 0.69
KDM4E B2RXH2 1/20 0.69
ALDH1A1 P00352 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
CYP3A4 P08684 1/20 0.69
CYP2C9 P11712 1/20 0.69
TSHR P16473 1/20 0.69
NFKB1 P19838 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phorbol SCHEMBL20582541 1.00 PRKCA (0.69) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL10620832 1.00 PRKCA (0.69) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL417521 1.00 PRKCA (0.69) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL27616694 1.00 PRKCA (0.69) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL27579226 0.96 PRKCA (0.67) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL21462215 0.92 PRKCA (0.66) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL5904049 0.92 PRKCA (0.60) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL27299282 0.90 PRKCA (0.63) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL7615331 0.90 PRKCA (0.62) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL64353 0.90 PRKCA (0.62) PRKCAPRKCGPRKD3PRKCBPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210139909-A1 SDF-1 Binding Nucleic Acids NOXXON PHARMA AG (DE) 2021-05-13 US disclosed
EP-2190991-B1 SDF-1 BINDING NUCLEIC ACIDS AND THE USE THEREOF NOXXON PHARMA AG (DE) 2019-11-06 EP disclosed
US-20180163207-A1 SDF-1 Binding Nucleic Acids NOXXON PHARMA AG (DE) 2018-06-14 US disclosed
US-9988636-B2 SDF-1 binding nucleic acids and the use thereof NOXXON PHARMA AG (DE) 2018-06-05 US disclosed
EP-2041282-B1 SDF-I BINDING NUCLEIC ACIDS NOXXON PHARMA AG (DE) 2018-01-03 EP disclosed
US-9822369-B2 SDF-1 binding nucleic acids NOXXON PHARMA AG (DE) 2017-11-21 US disclosed
US-20160326531-A1 SDF-1 Binding Nucleic Acids and the Use Thereof NOXXON PHARMA AG (DE) 2016-11-10 US disclosed
US-20150232853-A1 SDF-1 Binding Nucleic Acids TME Pharma AG (DE) 2015-08-20 US disclosed
US-9035038-B2 SDF-1 binding nucleic acids NOXXON PHARMA AG (DE) 2015-05-19 US disclosed
US-20140370034-A1 SDF-1 Binding Nucleic Acids and the Use Thereof NOXXON PHARMA AG (DE) 2014-12-18 US disclosed
US-8772257-B2 SDF-1 binding nucleic acids and the use thereof NOXXON PHARMA AG (DE) 2014-07-08 US disclosed
US-20130041019-A1 SDF-1 Binding Nucleic Acids NOXXON PHARMA AG (DE) 2013-02-14 US disclosed
US-8314223-B2 SDF-1 binding nucleic acids NOXXON PHARMA AG (DE) 2012-11-20 US disclosed
US-20110223127-A1 SDF-1 Binding Nucleic Acids And The Use Thereof NOXXON PHARMA AG (DE) 2011-09-15 US disclosed
US-20110112172-A1 SDF-1 Binding Nucleic Acids NOXXON PHARMA AG (DE) 2011-05-12 US disclosed
EP-2190991-A2 SDF-1 BINDING NUCLEIC ACIDS AND THE USE THEREOF Noxxon Pharma AG (DE) 2010-06-02 EP disclosed
EP-2041282-A2 SDF-I BINDING NUCLEIC ACIDS Noxxon Pharma AG (DE) 2009-04-01 EP disclosed
WO-2009019007-A2 SDF-1 BINDING NUCLEIC ACIDS AND THE USE THEREOF NOXXON PHARMA AG (DE) 2009-02-12 WO disclosed
WO-2008009437-A2 SDF-I BINDING NUCLEIC ACIDS NOXXON PHARMA AG (DE) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041019-A1 SDF-1 Binding Nucleic Acids CXCL12, CCL2, SDF4 PRKCA 2046/4885PRKCG 2133/4885PRKD3 2676/4885
US-20110112172-A1 SDF-1 Binding Nucleic Acids CXCL12, SDF4, CCL2 PRKCA 1516/4885PRKCG 1517/4885PRKD3 3336/4885
US-20160326531-A1 SDF-1 Binding Nucleic Acids and the Use Thereof CXCL12, SDF4, CXCR4 PRKCA 1735/4885PRKCG 1756/4885PRKD3 2501/4885
US-20110223127-A1 SDF-1 Binding Nucleic Acids And The Use Thereof CXCL12, SDF4, CXCR4 PRKCA 1735/4885PRKCG 1756/4885PRKD3 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.